Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Lobelane decreases methamphetamine self-administration in rats.

Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, Bardo MT.

Eur J Pharmacol. 2007 Sep 24;571(1):33-8. Epub 2007 Jun 13.

2.

Lobeline attenuates d-methamphetamine self-administration in rats.

Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, Bardo MT.

J Pharmacol Exp Ther. 2001 Jul;298(1):172-9.

3.

The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.

Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT.

J Pharmacol Exp Ther. 2010 Dec;335(3):841-51. doi: 10.1124/jpet.110.172742. Epub 2010 Aug 30.

4.

Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275. Epub 2009 Oct 23.

5.

Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2011 Oct;339(1):286-97. doi: 10.1124/jpet.111.184770. Epub 2011 Jul 21.

6.

The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.

Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, Bardo MT.

Psychopharmacology (Berl). 2012 Mar;220(2):395-403. doi: 10.1007/s00213-011-2488-9. Epub 2011 Sep 21.

7.

Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.

Wilmouth CE, Zheng G, Crooks PA, Dwoskin LP, Bardo MT.

Pharmacol Biochem Behav. 2013 Nov;112:29-33. doi: 10.1016/j.pbb.2013.09.006. Epub 2013 Sep 26.

8.

The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP.

Adv Pharmacol. 2014;69:71-106. doi: 10.1016/B978-0-12-420118-7.00002-0. Review.

9.

Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats.

Carson DS, Cornish JL, Guastella AJ, Hunt GE, McGregor IS.

Neuropharmacology. 2010 Jan;58(1):38-43. doi: 10.1016/j.neuropharm.2009.06.018. Epub 2009 Jun 26.

PMID:
19560473
10.

Effect of bupropion on nicotine self-administration in rats.

Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT.

Psychopharmacology (Berl). 2003 Aug;169(1):1-9. Epub 2003 Jun 17.

PMID:
12811464
11.

Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Nickell JR, Zheng G, Deaciuc AG, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2011 Mar;336(3):724-33. doi: 10.1124/jpet.110.172882. Epub 2010 Sep 28.

12.

Lobeline does not serve as a reinforcer in rats.

Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, Bardo MT.

Psychopharmacology (Berl). 2003 Feb;165(4):397-404. Epub 2002 Nov 30.

PMID:
12459929
13.

Bupropion attenuates methamphetamine self-administration in adult male rats.

Reichel CM, Murray JE, Grant KM, Bevins RA.

Drug Alcohol Depend. 2009 Feb 1;100(1-2):54-62. doi: 10.1016/j.drugalcdep.2008.09.006. Epub 2008 Nov 17.

14.

meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Horton DB, Siripurapu KB, Norrholm SD, Culver JP, Hojahmat M, Beckmann JS, Harrod SB, Deaciuc AG, Bardo MT, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2011 Mar;336(3):940-51. doi: 10.1124/jpet.110.175117. Epub 2010 Dec 21.

15.

Reboxetine: attenuation of intravenous nicotine self-administration in rats.

Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT.

J Pharmacol Exp Ther. 2002 Nov;303(2):664-72.

16.

Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA.

J Med Chem. 2005 Aug 25;48(17):5551-60.

17.

GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.

Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP.

Eur J Pharmacol. 2017 Jan 15;795:143-149. doi: 10.1016/j.ejphar.2016.12.016. Epub 2016 Dec 13.

PMID:
27986625
18.

The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats.

Pittenger ST, Barrett ST, Chou S, Bevins RA.

Behav Brain Res. 2016 Mar 1;300:150-9. doi: 10.1016/j.bbr.2015.11.033. Epub 2015 Nov 27.

19.

The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Orio L, Wee S, Newman AH, Pulvirenti L, Koob GF.

Addict Biol. 2010 Jul;15(3):312-23. doi: 10.1111/j.1369-1600.2010.00211.x. Epub 2010 Apr 29.

20.

GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.

Horton DB, Nickell JR, Zheng G, Crooks PA, Dwoskin LP.

J Neurochem. 2013 Oct;127(2):177-86. doi: 10.1111/jnc.12371. Epub 2013 Aug 19.

Supplemental Content

Support Center